2023 World Conference on Lung Cancer (Posters)-EP11.01. Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Does Histology Matter?

EP11.01. Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Does Histology Matter? - PDF(Slides)

Back to course

Pdf Summary

This study examined the impact of histology on the outcomes of non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (IO). The researchers analyzed 25 studies and found that IOs were associated with improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in both squamous cell carcinomas (SCC) and non-squamous cell carcinomas (nSCC) subtypes. There was no difference in these outcomes between SCC and nSCC, regardless of whether IO-based therapy was used as first line or second line treatment, or as IO alone or in combination with chemotherapy. Furthermore, there was no difference in disease-free survival (DFS) between SCC and nSCC in the adjuvant setting. These findings suggest that histology does not impact the efficacy of IO-based therapies in NSCLC. The researchers speculate that IOs may target a shared immune mechanism between both subtypes, bridging the gap in outcomes. The study also mentions ongoing subset analysis based on PD-L1 expression. In conclusion, the use of IO has improved outcomes for SCC and nSCC patients, regardless of histology, and further research is needed to understand the role of PD-L1 expression in predicting response to IO-based therapies.

Asset Subtitle

Khalil Choucair

Meta Tag

Speaker Khalil Choucair

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

histology

non-small cell lung cancer

NSCLC

immune checkpoint inhibitors

overall survival

progression-free survival

objective response rate

squamous cell carcinomas

non-squamous cell carcinomas

IO-based therapy